Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
Sodium Nitrite is an intravenous solution approved for treating acute cyanide poisoning by converting hemoglobin to methemoglobin, which binds cyanide and facilitates its elimination. It is a critical antidote administered in emergency settings for life-threatening cyanide exposure. The drug works through chemical conversion of hemoglobin to render cyanide non-toxic.
Stable specialty pharmaceutical with minimal competitive pressure; small commercial team typical for rare/emergency-use products.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite
Sodium Nitrite to Treat Arterial Aging
Pilot Study of Sodium Nitrite in Resuscitated Cardiac Arrest Patients
Safety and Efficacy of Sodium Nitrite in Sickle Cell Disease
Sodium Nitrite in Acute Myocardial Infarction
Worked on SODIUM NITRITE at Hope Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on Sodium Nitrite offers stability in a monopoly market but limited career scaling due to zero linked job openings and niche positioning. Ideal for professionals seeking depth in specialty/emergency pharmaceuticals or supply chain expertise in rare-use critical care products rather than high-growth brand scaling.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo